Neopharmed Gentili acquires the Italian Valeas and consolidates its presence in CNS, respiratory and paediatric areas
Milan, 25th July 2022 – Neopharmed Gentili, an Italian pharmaceutical company active in the marketing of high-value therapeutic solutions, controlled by Ardian in partnership with the Del Bono family, acquired 100% of Valeas, a historic Italian firm widely recognized for its leadership in the paediatric, broncho-pneumological, rhino-pneumatic and neuropsychiatric (CNS) areas. Thanks to this acquisition, Neopharmed Gentili will expand and complete its product portfolio with historic and widely recognized therapies in highly strategic areas.
Founded in Milan in 1934, where the company is also present with a manufacturing site, Valeas is a solid industrial firm active in the production and marketing of specific formulations for the treatment of diseases such as: chronic obstructive bronchitis, rhinopathy, upper and lower respiratory tract infections, anxiety, and insomnia.
Neopharmed Gentili has a proven track record in creating value through partnerships and acquisitions. This transaction perfectly fits with the strategy addressing external growth opportunities and will allow Neopharmed Gentili to consolidate its portfolio of therapeutic solutions in CNS – area of significant investments for the company – and significantly increase its presence in respiratory and paediatrics fields.
“The acquisition of Valeas is a further step toward expanding our commitment in the neuropsychiatric area, where we are present with drugs of proven efficacy for the treatment of anxiety disorders and insomnia, and toward consolidating our presence in respiratory and paediatrics areas with a broad portfolio of safe and effective products able to meet patients’ needs,” said Alessandro Del Bono, CEO of Neopharmed Gentili. The transaction confirms and further strengthens our development path and long-lasting growth, consolidating our positioning as a leading Italian pharmaceutical company, also expanding internationally.”
About Neopharmed Gentili
Neopharmed Gentili is a pharmaceutical company founded in Italy with historic roots in its territory, which is rapidly expanding beyond national borders thanks to a consolidated and reliable experience in M&A and Licensing transactions, especially with multinational partners. Research, responsibility, and care are the pillars that guide Neopharmed Gentili’s mission to improve the health and quality of life of patients, caregivers, and healthcare personnel. Neopharmed Gentili’s ambition is to help people live long and healthy lives, acting with ethical value and scientific precision, and offering solutions with high therapeutic value.
www.neogen.it
About Valeas
Valeas is a solid industrial company whose strength lies in the consolidated know-how and innovation. The company is active in research and development, production and marketing of pharmaceutical and nutraceutical products, with a widely recognized leadership in the Paediatric, Broncho-pneumological, Rhinoiatric and Neuropsychiatric fields. In its nearly 90-year history, the company has always been distinguished by its focus on quality and responsibility to patients.
www.valeas.it
For further informations:
Neopharmed Gentili S.p.A.
Ottavia Landi
Mob. 342.3409572 | o.landi@landi-consulting.com
Press office – Value Relations
Angela Del Giudice
Mob. 392.6858392 | a.delgiudice@vrelations.it
Chiara Farroni
Mob. 331.4997375 | c.farroni@vrelations.it
Download the PDF
Read the press review
